Ratioepo (epoetin theta)
- Region
- 🇪🇺 EU
- Active substance
- epoetin theta
- Company
- Ratiopharm GmbH
- Status
- Application withdrawn
- Therapeutic area
- Anemia; Kidney Failure; Cancer
- Application
- EMEA/H/C/001035
- ATC
- B03XA01
- Official record
- www.ema.europa.eu
Indication
Treatment of symptomatic anaemia associated with chronic renal failure in adult patients and treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Biopoin Authorised · Teva GmbH
- 🇪🇺 Eporatio Authorised · Ratiopharm GmbH
Follow Ratioepo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.